Article Text

Download PDFPDF
Eosinophils: a novel therapeutic target to promote liver regeneration in acute liver injury?
  1. Hong-Min Ni1,
  2. Amaya Lopez-Pascual2
  1. 1Department of Pharmacology, University of Kansas Medical Center, Kansas City, Kansas, USA
  2. 2Hepatology Unit CCUN, Navarra University Clinic, Pamplona, Navarre, Spain
  1. Correspondence to Dr Hong-Min Ni, Department of Pharmacology, University of Kansas Medical Center, Kansas City, Kansas, USA; hni{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The liver, the largest internal organ in the human body, is crucial in maintaining health and vitality. Acute liver injury (ALI) is a condition characterised by the death of hepatocytes due to necrosis and/or apoptosis. ALI can progress into a more severe and life-threatening condition known as acute liver failure (ALF). The major causes of ALI/ALF are drug-induced liver injury (DILI), viral and parasitic infections and hepatic ischaemia-reperfusion (IR) injury.1 Hepatic IR injury is a significant cause of liver injury that occurs in a variety of clinical contexts, including system shock, liver resection and liver transplantation. The underlying mechanisms of hepatic IR injury include oxygen and adenosine triphosphate (ATP) depletion, excessive inflammation, and the generation of reactive oxygen species following reperfusion. Liver transplantation is the standard treatment for end-stage liver diseases and ALF depending on the aetiology of the disease. However, the shortage of donor organs has limited the practice of liver transplantation. To address this issue, there is a growing acceptance of the use of liver grafts from extended criteria donors (ECD), which encompasses donors with steatotic liver, advanced age and donation after cardiac death (DCD). However, the use of ECD organs carries an increased risk of IR injury and mortality after …

View Full Text


  • Contributors Both authors contributed equally.

  • Funding This study was funded by Ministerio de Sanidad, Servicios Sociales e Igualdad (CD22/00109),National Institutes of HealthDK134737

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles